Phio Pharmaceuticals (NASDAQ: PHIO) announced on November 7, 2025 that its INTASYL compound PH-762 won the 2025 Immunomodulatory Solution of the Year award from the BioTech Breakthrough Awards program.The company is a clinical-stage biopharmaceutical developer using its proprietary INTASYL siRNA gene‑silencing platform focused on cancer therapies. Company leadership highlighted PH-762 as an intratumoral immunotherapy intended to enhance cancer treatment efficacy, and the award organization noted PH-762 addresses a medical need for non‑surgical options for cutaneous carcinomas.

Phio Pharmaceuticals (NASDAQ: PHIO) announced definitive agreements to exercise outstanding warrants to purchase an aggregate of 5,663,182 shares of common stock at exercise prices between $2.00 and $5.45, producing expected gross proceeds of approximately $13.4 million before placement agent fees and offering expenses.The offering closes in two tranches (first close on or about Nov 4, 2025, second close by Nov 18, 2025). Exercising holders will pay an additional $0.125 per new unregistered warrant ($1,415,795.50 aggregate) and receive new unregistered warrants to purchase up to 11,326,364 shares at a $2.05 exercise price, immediately exercisable with a 24‑month term following the resale registration effective date.Phio intends to use net proceeds for working capital and to accelerate development activities for PH-762 in cutaneous carcinomas after recent positive safety and pathology results.

Using AI to find stock market opportunities. Click to read StockQuakes, by StockQuakes Team, a Substack publication with hundreds of subscribers.

Pathologic Clearance: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third Patient Pathologic Results Assessed at Approximately 5 Weeks Safety Monitoring Committee Issues Favorable Review